Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab

University of Sao Paulo56 enrolled

Overview

The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Interventions

AcetazolamideDRUG

250 mg 1 hour before intravitreal injection

Brimonidine tartarateDRUG

1 drop 1 hour before intravitreal injection

Anterior chamber paracentesisPROCEDURE

Immediately after bevacizumab injection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of age related macular disease or diabetic retinopathy * Able and willing to provide informed consent Exclusion Criteria: * History of ocular hypertension or glaucoma * High Myopes (\> 6 spherical diopters) * High Hyperopes (\> 4 spherical diopters) * Pulmonary disease * Renal disease * Known allergy to any component of the study drug * Myocardial infarction, transient ischemic attack within 4 months prior to randomization or any contraindication for bevacizumab use

Outcomes

Primary Outcomes

Intraocular pressure (mmHg)

Time frame: 1 hour and, 3 minutes before IVI. 3,10,20, 30 minutes after IVI

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.